ADVOS procedure supports main organs of acid-base balance
The mortality rate of COVID-19 patients with multi-organ failure is high, especially when the main detoxification organs of liver, lung and kidney have limited function. These three organs are also the main organs to maintain acid-base balance in the physiological range.
The ADVOS (ADVanced Organ Support) procedure takes a new approach. It is the world’s first blood purification procedure for combined multi-organ support of the liver, lungs, kidneys, and acid-base balance – in other words, a 4-in-1 therapy. Through the direct acid removal of the ADVOS procedure, all three organs can be directly supported for the normalization of the acid-base balance.
Study shows therapy success
In a new study conducted by the II Medical Clinic of the Klinikum rechts der Isar of the Technical University of Munich, the focus was on the ability of the ADVOS procedure to support the role of the lungs in acid-base balance. The aim of the study was to evaluate the ADVOS system as a treatment option in predominantly elderly COVID-19 patients with multiple organ failure and problems with carbon dioxide removal.
For the patients in the study, rapid correction of acid-base balance and continuous carbon dioxide removal were achieved during ADVOS treatments. In addition, a significant normalization of blood pH was realized after the first ADVOS treatment.
Over the treatment period, it was thus possible to rapidly normalize one of the strongest risk factors for increased mortality in COVID-19 patients with acute respiratory distress syndrome and multiple organ failure.
The study thus demonstrates that the ADVOS therapy can positively impact the treatment of critically ill COVID-19 patients.
If you would like to read the entire study, please visit Extracorporeal carbon dioxide Removal (ECCO2R) with the Advanced Organ Support (ADVOS) system in critically ill COVID‐19 patients – Allescher – – Artificial Organs – Wiley Online Library
The Munich based ADVITOS GmbH developed the CE-marked and globally patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi-organ support integrated in one single device. The ADVOS therapy improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung, and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO2 (lungs). In addition, the ADVOS therapy enables treatment of acid-base disbalances through patient-individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading hospitals throughout Germany and is on its way to entering the international market. ADVITOS receives funding from the European Union’s Horizon 2020 research and innovation programme.
Telefon: +49 (89) 4111842-27
Telefon: +49 (170) 4583383